Citigroup Inc Nuvectis Pharma, Inc. Call Options Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NVCT
# of Institutions
32Shares Held
1.65MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$2.84 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA301KShares$1.52 Million0.0% of portfolio
-
Baldwin Brothers LLC174KShares$877,6150.08% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$420,3960.0% of portfolio
-
Geode Capital Management, LLC Boston, MA79.7KShares$401,7680.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $73.8M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...